Unilateral vasectomy for intractable epididiymo-orchitis in patients with anorectal malformation.

BACKGROUND: Male patients treated for anorectal malformations (ARM) and recto-urethral fistula (RUF) tend to develop recurrent epididymo-orchitis (EO) which occurs approximately in 20% of all them. The optimal management of this condition is unclear because of the extreme its rarity and the unavailability of detailed analysis in literature. To date the majority of this patients benefits from medical treatment and symptoms reduce over time but few data have been published in literature about management of patients with intractable EO. OBJECTIVE: To describe the efficacy of unilateral vasectomy in patients operated on for anorectal malformations with RUF and affected by intractable EO. STUDY DESIGN: We present five patients who met the criteria for intractable EO, and followed at our centre four of whom have undergone unilateral vasectomy. RESULTS: The first episode of EO presented at 42,00 mos ±29.39. Initially, patients were all managed with analgesics and antibiotics. For the failure of therapy, five patients were all offered unilateral vasectomy but only four families accepted procedure. Surgical treatment was performed as a day case without complications. Postoperative follow up was 88,50 mos ±68.36. Prompt and durable resolution of symptoms was observed. DISCUSSION: The long-term effects of recurrent EO in ARM are often underestimated. Prompt and appropriate intervention should prevent this undesirable sequela. Unfortunately, the optimal management of this complication is unclear, partly because of its extreme rarity. The established management needs to follow the route of correcting underlying anomalies and providing long-term analgesic and antibiotics but this may have undesired side effects. We therefore offered families vasectomy for complete symptom resolution and/or drug withdrawal. Vasectomy, as a form of treatment for, can be justified if it can prevent pain, infection and destruction of the testes. Early vasectomy may save enough functional testis tissue. CONCLUSION: To date, the only available treatment to achieve definitive resolution of symptoms in intractable unilateral EO is vasectomy. Long-term effects of such procedure on fertility are unknown. The treatment of recurrent EO in cases without site predilection remains a matter of contention.

[Intussusception after congenital diaphragmatic hernia repair]. / Invagination intestinale après réparation d'une hernie diaphragmatique congénitale.

INTRODUCTION: Bowel intussusception is a common complication of abdominal surgery. However, the literature on intussusception after congenital diaphragmatic hernia (CDH) repair is scarce. CASE REPORT: A 24-month-old female was admitted with vomiting, crying and leukocytosis, with no objective abdominal signs. The chest x-ray showed the presence of bowel in the left hemithorax. Surgical exposure reduced a hernia across a Bochdalek defect, involving part of the left colon and the transverse colon. On the 7th postoperative day, the patient had symptoms of intestinal obstruction with worsening of her general condition. The explorative laparotomy evidenced an ileoileal intussusception, 15 cm from the ileocecal valve, in absence of a leading point. CONCLUSION: A postoperative intussusception in a similar case could be explained by atony of the herniated bowel, possibly a functional leading point in the postoperative phase, when the peristalsis is reactivated.

A 4-years-old girl with a mesenteric cyst.

This Letter to the Editor deals with the case of a 4-years-old female affected by a mesenteric cyst, initially confused with an ovarian cyst. The emergency situation justified our open approach. However, as expressed by the Authors, a laparoscopy should be always considered, also in pediatric age.

Amyand's hernia in premature twins.

Amyand's hernia (AH) is the presence of a normal or inflamed vermiform appendix in an inguinal hernia sac. This condition is unusual in neonates and in infants, and it has not been described in premature twins. We present two 32-day-old biovular twins with a right AH, treated with sparing of the appendix and herniotomy. The correct management of AH is discussed via a brief review of the literature.

Controlled coupling of counterpropagating whispering-gallery modes by a single Rayleigh scatterer: a classical problem in a quantum optical light.

We present experiments where a single subwavelength scatterer is used to examine and control the backscattering induced coupling between counterpropagating high-Q modes of a microsphere resonator. Our measurements reveal the standing wave character of the resulting symmetric and antisymmetric eigenmodes, their unbalanced intensity distributions, and the coherent nature of their coupling. We discuss our findings and the underlying classical physics in the framework common to quantum optics and provide a particularly intuitive explanation of the central processes.

Controlled photon transfer between two individual nanoemitters via shared high-Q modes of a microsphere resonator.

We realize controlled cavity-mediated photon transfer between two single nanoparticles over a distance of several tens of micrometers. First, we show how a single nanoscopic emitter attached to a near-field probe can be coupled to high-Q whispering-gallery modes of a silica microsphere at will. Then we demonstrate transfer of energy between this and a second nanoparticle deposited on the sphere surface. We estimate the photon transfer efficiency to be about 6 orders of magnitude higher than that via free-space propagation at comparable separations.

Multidisciplinary approach for diagnosing syncope: a retrospective study on 521 outpatients.

OBJECTIVES: To describe causes of syncope in outpatients in whom structural heart disease was ruled out as a cause, and to analyse the role of a multidisciplinary approach in a syncope unit for the diagnosis of patients with syncope of unknown origin. METHODS: Cardiovascular autonomic nervous system (ANS) function was evaluated extensively in 521 outpatients by careful history, physical examination including orthostatic blood pressure measurement and standard ECG, and tilt testing. RESULTS: Causes of syncope remained unknown in 29.2% of cases. ANS dysfunction was found in 58.6% of those presenting with either neurally mediated syncope (53.6%) or chronic autonomic failure (5%); 3.8% of the patients suffered from syncope of cardiogenic origin (2.5%) or non-neurogenic hypotension (1.3%), and 8.4% had loss of consciousness of non-syncopal origin. Loss of consciousness was confirmed as being related to seizures in under 30% of patients initially diagnosed as having epilepsy. CONCLUSIONS: Neurally mediated syncope represents the commonest type of syncope. ANS evaluation including tilt testing should be considered as preliminary screening in patients with syncope in the absence of definite heart abnormalities. Neurologists should consider syncope from ANS failure as a comorbid factor in patients with seizures where the clinical characteristics are not straightforward.

Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.

The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial. Sixty-three patients with MBC, previously treated with chemotherapy including anthracycline and/or taxanes, were treated with mitoxantrone 10 or 12 mg m(-2) intravenously on day 1 plus gemcitabine in escalating doses from 600 to 1200 mg m(-2) intravenously on days 1 and 8, every 3 weeks. In phase I, on 23 patients entered on study, dose-limiting toxicity occurred at the dosage of 1200 mg m(-2) gemcitabine and 10 mg m(-2) mitoxantrone, with three out of five patients developing grade 4 neutropenia. In phase II, with gemcitabine administered at 1000 mg m(-2) and mitoxantrone at 10 mg m(-2), 12 (30%) out of 40 assessable patients responded, even if no complete response was obtained. Moreover, stable disease was observed in eight (20%) patients. The median time to treatment failure was 22 weeks (range, 2-33), and median survival was 42 weeks (range, 2-92). Grade 3 and 4 neutropenia were observed in 12 (30%) and one (2.5%) cases respectively; grade 3 thrombocytopenia was observed in two patients (5%), grade 2 mucositis in two patients (5%), grade 3 anaemia in two patients (5%), grade 3 alopecia in one patient (2.5%) and asymptomatic cardiotoxicity in three patients (8%), respectively. In conclusion, the doses of 10 mg m(-2) (day 1) for mitoxantrone and 1000 mg m(-2) for gemcitabine (days 1-8) every 3 weeks resulted active and safe in MBC. Further investigations in less heavily pretreated patients are warranted.

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.

A potential way to improve the results obtained with the standard carboplatin/cisplatin (CDDP)-paclitaxel treatment regimen in advanced ovarian cancer is to incorporate a modulating agent such as lonidamine (LND). In fact, LND has been shown to revert the resistance to cisplatin and to potentiate cisplatin activity experimental models and in clinical studies. 35 consecutive patients with advanced ovarian cancer, not previously treated with chemotherapy were treated with paclitaxel at a dose of 135 mg/m(2) intravenously (i.v.) on day 1 (in a 3 h infusion) and cisplatin at a dose of 75 mg/m(2) iv on day 2 plus LND orally (p.o.) at a dose of 450 mg/die for 6 consecutive days starting two days before chemotherapy, every 3 weeks for six cycles. Complete plus partial responses were observed in 8 (80%) out of the 10 women with measurable disease. In the 25 patients with evaluable disease, only four clinical progressions were observed (16%). Median progression-free survival (PFS) and overall survival (OS) were 28.5 (95% confidence interval (CI) 22.2-34.8) and 46.5 (95% CI 32.4-60.00) months respectively. Grade 3-4 neutropenia was observed in 9 (26%) patients. Alopecia, nausea and vomiting (Grade 3) were observed in 33 (94%) and 5 (14%) patients, respectively. In conclusion, the combination of CDDP/paclitaxel plus LND is active and tolerable in the treatment of advanced ovarian cancer.

Angiomatosis bacilar / Bacillary angiomatosis

La angiomatosis bacilar (AB) es un proceso patológico caracterizado por la prolifración vascular secundaria a microorganismos del género Bartonella. Se ha asociado comúnmente con pacientes HIV positivos, pero también ha sido reportado en otros pacientes inmunodeprimidos y en un pequeño grupo de pacientes sin inmuno-supresión demostrada. Se caracteriza por lesiones cutáneas vasculares que pueden diseminarse sistémicamente. La angiomatosis bacilar es tratable y puede ser curada con tratamiento antibiótico

Angiomatosis bacilar / Bacillary angiomatosis

La angiomatosis bacilar (AB) es un proceso patológico caracterizado por la prolifración vascular secundaria a microorganismos del género Bartonella. Se ha asociado comúnmente con pacientes HIV positivos, pero también ha sido reportado en otros pacientes inmunodeprimidos y en un pequeño grupo de pacientes sin inmuno-supresión demostrada. Se caracteriza por lesiones cutáneas vasculares que pueden diseminarse sistémicamente. La angiomatosis bacilar es tratable y puede ser curada con tratamiento antibiótico(AU)

New aromatase inhibitors in the treatment of advanced breast cancer.

New aromatase inhibitors are an exciting treatment option for postmenopausal women with hormone sensitive breast cancer. They have been shown to reduce tumors in a significant number of patients, and exhibit definite antitumor activity at a relatively low daily dose, and are highly potent, highly selective, and well-tolerated. Results from recent clinical phase III studies have confirmed their efficacy and the key role they have in the therapy for advanced breast cancer in postmenopausal women. The agents available for clinical use are: letrozole, anastrozole, and exemestane. These drugs have demonstrated high activity in women failing tamoxifen in locally advanced or metastatic disease. This communication reviews the clinical use of aromatase inhibitors, particularly in second and first line hormonal treatment of advanced breast cancer.

Disease management program improves asthma outcomes.

OBJECTIVE: To show that a disease management program that empowers patients with asthma to participate in the management of their condition can improve quality of life and reduce the use of medical services. STUDY DESIGN: Utilization and quality-of-life data were tracked to identify outcome changes in patients with moderate to severe asthma. Baseline measures were used as a control and were compared with measures taken at 6 and 12 months after enrollment. PATIENTS AND METHODS: Study participants were from a single Medicaid managed care plan in western Pennsylvania. Patients' quality of life during their participation in the program was tracked through an outside pharmacoepidemiologic research firm. Utilization data were updated with every interaction between a patient and case management nurse. RESULTS: Both quality-of-life and utilization data show statistically significant improvements at 6 months. Further, 12-month data show improvement that is statistically significant in all measures with the exception of the adult quality-of-life measure, where a small sample size limited the statistical results. CONCLUSIONS: A collaborative, proactive approach to asthma management improves patients' quality of life and reduces use of costly medical services.

High efficacy of paclitaxel and doxorubicin as first-line therapy in advanced breast cancer: a phase I-II study.

The aim of this study was to define the maximum tolerated dose (MTD) of paclitaxel (TAX) in combination with doxorubicin (ADM). To evaluate the efficacy and tolerability of this combination, TAX was administered in escalating doses of 30 mg/m2, starting from 120 mg/m2, by 1 hour continuous infusion, per group of three patients; ADM was administered at a fixed dose of 50 mg/m2, 24 hours before administering TAX (phase 1). The combination was recycled every 3 weeks. In phase II, TAX was administered at the MTD defined in phase I. Thirty-six women were enrolled. The MTD of TAX was 220 mg/m2. Objective responses were observed in 28/34 (82%) assessable patients. The median progression-free survival was 11.8 months and overall survival 27.8 months. The main clinical toxicity was neutropenia (grade III-IV) of short duration (94%). Two patients developed cardiac toxicity. The combination TAX+ADM is very effective in advanced breast cancer.

Sindrome de Sweet / Sweets syndrome

El sindrome de Sweet fue descripto por primera vez por Robert Douglas Sweet en 1964. Se presenta con mayor frecuencia en el sexo femenino con un pico méximo en la quinta decada despues de una infección del tracto respiratorio o gastrointestinal. Clínicamente se caracteriza por la apición de placas eritematosas dolorosas con pseudoampollas y ocacionalmenmte póstulas en cara, neriz, cuello y extremidades acompañadas por fiebrte y malestar general. Histológicamente se caracteriza por un denso infiltrado de neutrófilos en la dermis. La etiopatogenia es poco conocida. Se mencionan conceptos sobre inmunocomplejos-vaculitis, activación de células T y alteración de la función del neutrófilo, pero ninguno es definitivamente sostenido por resultados experimentales. El síndrome de Sweet puede presentarse asociado a procesos inflamatorios (infecciones, enfermedades autoinmunes, neoplasias de origen hemmatológico y tumores sólidos). Los corticoides sistémicos se han considerado como tratamiento de elección aunque otros tratamientos han sido usados incluyendo colchicina, ioduro de potasio, sulfonas, clofazimine con limitado éxito

Sindrome de Sweet / Sweets syndrome

El sindrome de Sweet fue descripto por primera vez por Robert Douglas Sweet en 1964. Se presenta con mayor frecuencia en el sexo femenino con un pico méximo en la quinta decada despues de una infección del tracto respiratorio o gastrointestinal. Clínicamente se caracteriza por la apición de placas eritematosas dolorosas con pseudoampollas y ocacionalmenmte póstulas en cara, neriz, cuello y extremidades acompañadas por fiebrte y malestar general. Histológicamente se caracteriza por un denso infiltrado de neutrófilos en la dermis. La etiopatogenia es poco conocida. Se mencionan conceptos sobre inmunocomplejos-vaculitis, activación de células T y alteración de la función del neutrófilo, pero ninguno es definitivamente sostenido por resultados experimentales. El síndrome de Sweet puede presentarse asociado a procesos inflamatorios (infecciones, enfermedades autoinmunes, neoplasias de origen hemmatológico y tumores sólidos). Los corticoides sistémicos se han considerado como tratamiento de elección aunque otros tratamientos han sido usados incluyendo colchicina, ioduro de potasio, sulfonas, clofazimine con limitado éxito(AU)

Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy.

BACKGROUND: An emotional campaign promoting the Di Bella cancer therapy was launched by the Italian media in 1997. Its effects on patients' hopes, feelings, and decision-making processes were largely unknown. We undertook an investigation of this issue. METHODS: Between Feb 25 and March 31, 1998, a ten-item questionnaire was distributed to 1300 unselected adult patients attending 13 cancer centres throughout Italy. Four expert psycho-oncologists reviewed the design and validity of the contents of the questionnaire. Sociodemographic information was also collected. FINDINGS: 1120 (86%) questionnaires were returned and analysed. The main sources of information were television/radio (62%) and newspapers (26%); only 5% cited doctors. The campaign induced optimism in the patients about the efficacy of the method (ineffective 1%, effective 42%, uncertain 57%), and 53% said their hope of cure was increased. However, 48% felt more confused. 24% do not discuss new treatments with their oncologists, and 20% would like to but cannot. When choosing a treatment, the advice of a trusted doctor was judged more important than scientific progress (53% vs 32%) and 63% would try even unproven treatments in the hope of a cure. Replies to many of the questions were influenced by patients' educational attainment and by the degree of communication with their oncologists. INTERPRETATION: Science cannot prevent the harm caused by such campaigns and their psychological consequences, particularly for less educated patients. When making decisions, patients are looking for hope from the treatment and trust in their doctor, both of which depend on effective doctor-patient communications that therefore need to be improved.

Nonsyndromal overgrowth in males with mild psychomotor delay.

Over the last 3 years we ascertained 42 patients for statural overgrowth and/or macrocephaly, who also had mild developmental delay. There were 39 males and three females, two of whom were sisters. In no case was tall stature a familial characteristic. Family history was unremarkable, except for the case of the two sisters. Physical examination did not demonstrate any consistent pattern of malformations or anomalies identifying a syndrome, known or unknown. Chromosomes were apparently normal and the molecular test for the fragile X syndrome yielded normal results in all cases. Muscular hypotonia, advanced bone age, and epilepsy were relatively consistent manifestations. The hypothalamus-pituitary axis seemed to be intact when tested through the blood levels of insulin-like growth factors I and II and of the insulin-like growth binding protein 3, and the excess of growth was apparently growth hormone independent. The condition comprising excessive growth, developmental delay, muscular hypotonia, absence of a consistent pattern of physical anomalies, and apparently sporadic occurrence, largely limited to males, may be heterogenous.

[Molecular biology of dengue virus]. / Biología molecular del virus dengue.

In Venezuela the problem of Dengue infection has become worst during the last decade, turning the country into an hyperendemic region where three of the four serotypes co-circulate. The Dengue has become a problem of Public Health, so the knowledge of the virus, its life cycle and characteristics, as well as the different aspects related with its biology are extremely important to fight the virus and for the develop of a vaccine. In a general way, the present work describes different aspects related to the molecular biology of the Dengue virus and its life cycle: the structure, composition, production of structural and non structural protein and its relation to the replication cycle of the virus. Some aspects related with the assembly and release of particles from infected cells are also discussed. With this a general view of the molecular biology of the Dengue virus and its replication in the host cell is shown.